Class Action Lawsuit Filed Against Alto Neuroscience, Inc.

Attorney Bronstein, Gewirtz & Grossman, LLC has notified investors that a class action lawsuit has been filed against Alto Neuroscience, Inc. and certain of its officers. The lawsuit seeks to recover damages for alleged violations of federal securities laws on behalf of investors who purchased or acquired Alto common stock between February 2, 2024, and October 22, 2024. The complaint alleges that defendants made false and misleading statements about the effectiveness of their treatment for major depressive disorder (MDD), leading to an overstatement of the company's business and financial prospects.

Key Takeaways:

• The lawsuit alleges that Alto Neuroscience, Inc. and its officers made false and misleading statements about the effectiveness of their treatment for major depressive disorder (MDD).
• The class action lawsuit seeks to recover damages for investors who purchased or acquired Alto common stock between February 2, 2024, and October 22, 2024.
• The complaint alleges that the company's business and financial prospects were overstated due to the false statements about the effectiveness of ALTO-100.
• Bronstein, Gewirtz & Grossman, LLC has a track record of recovering hundreds of millions of dollars for investors nationwide.
• Investors have until September 19, 2025, to request that the Court appoint them as lead plaintiff.
• The law firm represents investors on a contingency fee basis, with no upfront costs required.

Statistics:

• The lawsuit covers a period of approximately 8 months, from February 2, 2024, to October 22, 2024.
• The complaint alleges that Alto Neuroscience, Inc.'s business and financial prospects were overstated.
• Bronstein, Gewirtz & Grossman, LLC has recovered hundreds of millions of dollars for investors nationwide.

Sources:

• Bronstein, Gewirtz & Grossman, LLC
• GLOBE NEWSWIRE, New York, July 28, 2025